evipedia.ai
← Back

GHRP-2 for Health & Longevity

Created on 10/28/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

GHRP-2, a laboratory-made protein fragment that copies the hunger hormone ghrelin, triggers bursts of the body's own growth hormone and draws interest for muscle and healthy aging. Its one approved use, a single-dose test for growth hormone deficiency in Japan, is well supported. It raises growth hormone and hunger, but no study has shown better muscle function, body composition, sleep or lifespan in adults; longer-term concerns rest on indirect evidence. (Full Review)

Protocol

Clinic regimen
100 µg subcutaneously
With GHRP-6 and sermorelin, in men on testosterone; diagnostic regimen: one 100 µg intravenous dose, fasting
Single or split dosing
2–3 times daily
Short 0.42–0.69 hour half-life; a review reports continuous exposure desensitizes more than intermittent dosing
Time of day
Fasting, often at bedtime
As the label directs; a late-night dose did not deepen sleep
Time to effect
GH peak
15–60 minutes
After an intravenous dose; one brief GH pulse per dose
Body composition
Months
By analogy with ibutamoren; no trial has measured it for GHRP-2
IGF-1 rise
Within a day
Hormone levels only; no study links GHRP-2-raised IGF-1 to health outcomes

Benefits

Contraindications
  • Pregnant women or those who may be pregnant
  • Acute critical illness (after open-heart or abdominal surgery, multiple trauma, or acute respiratory failure)
  • Active malignancy
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Untreated pituitary adenoma
  • Insulin-treated or poorly controlled diabetes
  • Athletes tested under the World Anti-Doping Code
  • Known high prolactin or prolactinoma
    •
Key Interactions
  • GHRH and its analogues (sermorelin, tesamorelin): synergistic GH release, larger IGF-1 increases
  • Oral estradiol therapy: amplified GH secretion
  • Aromatase inhibitors (anastrozole, letrozole) and tamoxifen: smaller IGF-1 rises
  • Glucocorticoids (prednisone, dexamethasone): blunted GH response
  • Insulin and other glucose-lowering drugs (metformin, sulfonylureas): increased insulin requirement reported
  • Other pituitary test agents (TRH, GnRH, CRH): no established safety record for co-administration
  • L-arginine (supplement): larger GH pulse
  • Somatostatin analogues (octreotide, lanreotide): reduced effect
  • Nicotinic acid and its analogues (niacin, acipimox): greater GH and IGF-1 exposure
  • Recombinant GH (somatropin): excess IGF-1, fluid retention and glucose rise
  • Other ghrelin-receptor agonists (ibutamoren, ipamorelin): additive cortisol, prolactin, appetite and glucose effects
  • Food and exercise: meals blunt the GH response; strenuous exercise adds to it
    •
Theoretical (inferred from mechanism)
  • Prolactin-raising drugs (risperidone, haloperidol): high prolactin
  • Blood pressure-lowering drugs (amlodipine, lisinopril): dizziness or fainting
  • Sedating over-the-counter antihistamines (diphenhydramine, doxylamine): impaired alertness
    •

Risk & Side Effects

  • High:
  • Medium: Warmth, sweating and other acute reactions
    •
  • Low: Raised blood sugar and reduced insulin sensitivity; death and serious complications in critical illness; fluid retention and muscle or joint pain; cancer risk from sustained IGF-1 elevation; pituitary apoplexy in people with pituitary tumors
    •
  • Speculative: Cortisol and prolactin elevation; immunogenicity and contaminated products
    •

Monitoring

Marker Target Why
IGF-1 Within the age-adjusted reference range, not above its upper limit Shows effect and excess
Fasting glucose 70–99 mg/dL Safety check; rise changes use
HbA1c 4.0–5.6% Safety check; rise changes use
Prolactin Men about 2–18 ng/mL; non-pregnant women about 2–29 ng/mL Safety check; persistent rise changes use
Morning cortisol About 5–25 µg/dL at 8 a.m. Safety check; persistent rise changes use
ALT About 7–56 U/L Safety check; labeled liver-enzyme rise
White blood cell count About 4.5–11.0 × 10⁹/L Safety check; labeled rise
Pregnancy test Negative Pregnancy is a contraindication

Cadence: Baseline panel, including a pregnancy test for women who could become pregnant, before starting; IGF-1 and fasting glucose at 4–6 weeks, then every 3 months while in use; HbA1c every 3 months; prolactin, morning cortisol, ALT and white blood cell count at 3 months, then every 6 months; abnormal hormone results repeated after stopping.

Qualitative Assessment

  • Hunger and appetite between meals
  • Sleep quality and daytime drowsiness
  • Swelling of hands or feet, tingling in the fingers
  • Joint or muscle aches
  • Warmth or flushing after doses
  • Injection-site redness or pain
  • Energy, exercise recovery and waist circumference
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.